Search results with tag "Approved patient labeling"
FDA-Approved Patient Labeling NEXPLANON (etonogestrel ...
www.organon.com1 FDA-Approved Patient Labeling NEXPLANON (etonogestrel implant) Radiopaque Subdermal Use Only NEXPLANON does not protect against HIV infection (the virus that causes AIDS) or other sexually transmitted diseases. Read this Patient Information leaflet carefully before you decide if NEXPLANON is right for you.
HIGHLIGHTS OF PRESCRIBING INFORMATION • These …
labeling.bayerhealthcare.comSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling Revised: 7/2021 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1. Dosing Over Time 2.2. Insertion Instructions 2.3 Patient Follow-up 2.4 Removal of Skyla 2.5 Continuation of Contraception after Removal 3 …
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
labeling.bayerhealthcare.comSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling Revised: 8/2021 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 1.1. Contraception 1.2 Heavy Menstrual Bleeding 2 DOSAGE AND ADMINISTRATION 2.1 Dosing Over Time 2.2 Insertion Instructions 2.3 Patient Follow-up 2.4 Removal of Mirena
HIGHLIGHTS OF PRESCRIBING INFORMATION • These …
labeling.bayerhealthcare.comSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling Revised: 7/2021 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1. Dosing Over Time 2.2. Insertion Instructions 2.3 Patient Follow-up 2.4 Removal of Skyla 2.5 Continuation of Contraception after Removal 3 DOSAGE FORMS AND ...
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.merck.comSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 10/2016 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Important Administration Instructions 2.2 DosingRecommendations in Adults 2.3 Preparation and Administration 3 DOSAGE FORMS …
FULL PRESCRIBING INFORMATION: CONTENTS*
pi.lilly.comSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling Revised: 02/2018 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 1.1 Erectile Dysfunction 1.2 Benign Prostatic Hyperplasia 1.3 Erectile Dysfunction and Benign Prostatic Hyperplasia 1.4 Limitation of Use 2 DOSAGE AND ADMINISTRATION
HIGHLIGHTS OF PRESCRIBING INFORMATION …
media.allergan.comSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 03/2021 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosage 2.2 Dosage Modifications 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 6 ADVERSE …
17.5 FDA-Approved Patient Labeling - Taclonex
www.taclonex.com17.4 Excessive Exposure to Light Patients who apply Taclonex® Ointment to exposed portions of the body should avoi d excessive exposure to either natural or artificial ...
CALQUENCE PRESCRIBING INFORMATION
www.azpicentral.comSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 11/2019 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 1.1 Mantle Cell Lymphoma 1.2 Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosage 2.2 …
To report SUSPECTED ADVERSE REACTIONS, contact Myovant
www.myovant.comFDA-approved patient labeling. Revised: 12/2020 FULL PRESCRIBING INFORMATION: CONTENTS * 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosage 2.2 Dose Modification for Use with P-gp Inhibitors 2.3 Dose Modification for Use with Combined P-gp and Strong CYP3A Inducers ...